678 Efficacy of Upadacitinib as an Induction Therapy in Severe and Refractory Ulcerative Colitis: Sub-Group Analysis of the Phase 2b Study U-ACHIEVE
Geert D’Haens(Amsterdam University Medical Centers), Remo Panaccione(University of Calgary), Fabio Cataldi(Pfizer (United States)), James O. Lindsay(Barts Health NHS Trust), Edward V. Loftus(Mayo Clinic), Wen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wangang Xie(AbbVie (United States)), David Pugatch
Cited by 0
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
|Journal of Crohn s and Colitis|2009|897
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
|Gastroenterology|1998|865
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
|Gastroenterology|2010|781
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558